Evaxion Secures $30M Capital Boost, Licenses Vaccine to Merck
Event summary
- Evaxion licensed its infectious disease vaccine candidate EVX-B3 to Merck for $7.5M upfront, with $592M in potential milestone payments.
- The company raised over $30M in 2025, extending its cash runway into mid-2027.
- Evaxion's personalized cancer vaccine EVX-01 showed a 75% objective response rate in phase 2 trials.
- The company added two new vaccine candidates to its pipeline: EVX-04 for AML and EVX-B4 for Group A Streptococcus.
- Evaxion received the Galien Foundation Prix Bridges Award for AI-Immunology™.
The big picture
Evaxion's strategic validation through Merck's licensing deal and strong phase 2 data positions it as a key player in AI-driven vaccine development. The company's ability to attract significant capital and partnerships underscores the growing industry interest in AI-Immunology™. However, sustaining this momentum will depend on its ability to deliver on clinical milestones and expand its pipeline into new therapeutic areas.
What we're watching
- Pipeline Expansion
- Whether Evaxion can sustain the momentum of its AI-Immunology™ platform by successfully advancing its new autoimmune disease program.
- Partnership Dynamics
- How Evaxion's ability to secure additional high-value partnerships will impact its long-term revenue growth.
- Clinical Validation
- The pace at which Evaxion can translate its promising phase 2 data for EVX-01 into phase 3 trials and potential regulatory approval.
Related topics